Predictive Oncology joins race to develop Covid-19 vaccine

Predictive Oncology has joined the race to develop a Covid-19 vaccine with the acquisition of Soluble Therapeutics, followed by collaboration and licensing of a new nanoparticle vaccine technology platform. The vaccine technology, based on a self-assembling nanoparticle called NSP1, has surface properties enabling the rapid design and display of viral receptor stems for virtually all viruses. Pharmaceutical Technology